After Pfizer, Russias Sputnik V Shows 92% Efficacy Against Coronavirus

Supported by

The Sputnik V vaccine candidate has shown ‘high efficacy’ in interim data, demonstrating 92 per cent effectiveness against COVID-19, Russian authorities have said.

The announcement comes two days after American drug major Pfizer released interim information that showed its COVID-19 vaccine was over 90 per cent effective.

While Pfizer’s interim data was collected from over 43,500 participants, the Sputnik V findings evaluated some 16,000 participants, a spokesperson for the Russian Direct Investment Fund (RDIF) said.

The Russian sovereign wealth fund has partnered with Dr Reddy’s to test the vaccine in India.

‘The confirmation is based on the first interim data from the largest double-blind, randomised, placebo-controlled Phase III clinical trials in Russia involving 40,000 volunteers,’ RDIF said in a release.

‘The trials evaluated efficacy among over 16,000 volunteers who received the vaccine or placebo 21 days after the first injection. As a result of a statistical analysis of 20 confirmed cases of coronavirus, the case split between vaccinated individuals and those who received the placebo indicates that the Sputnik V vaccine had an efficacy rate of 92 per cent after the second dose,’ it said.

‘There are two forms of the Sputnik V vaccine – liquid, which would have to be stored at minus 18°C and lyophilised (freeze dried), which can be stored at 2°C to 8°C. The lyophilised form was developed especially for the transportation of the vaccine to remote places, as Russia is a very big country,’ the RDIF spokesperson said.

‘India is also a very big country…the vaccine was developed considering the big distance that it would have to travel to reach the remote areas,’ he added.

Sputnik V is a human adenovirus vaccine that uses two weakened and genetically modified common cold viruses to carry the code for the cells in the human body to build the COVID-19 spike protein.

The body’s immune system is expected to recognise this spike protein as a threat and develop an immune response to fight it, so that the real covid-19 virus would not be able to infect when it tries to attack.

Also Read: India Records 47,905 Fresh COVID-19 Cases In 24 Hours: 10 Points

#PoweredByYou We bring you news and stories that are worth your attention! Stories that are relevant, reliable, contextual and unbiased. If you read us, watch us, and like what we do, then show us some love! Good journalism is expensive to produce and we have come this far only with your support. Keep encouraging independent media organisations and independent journalists. We always want to remain answerable to you and not to anyone else.

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Amplified by

P&G Shiksha

P&G Shiksha Turns 20 And These Stories Say It All

Amplified by

Isha Foundation

Sadhguru’s Meditation App ‘Miracle of Mind’ Hits 1 Million Downloads in 15 Hours, Surpassing ChatGPT’s Early Growth

Recent Stories

Denied Tree-Cutting Permit, Bihar Authorities Build ₹100 Crore Road Curving Around Trees

38 Hours After Ahmedabad Crash, Air India Boeing 777 Drops 900 Ft Post-Takeoff; DGCA Grounds Pilots, Launches Probe

Delhi Court Closes CBI Probe in JNU Student Najeeb Ahmed’s 2016 Disappearance; Mother Vows to Keep Fighting

Contributors

Writer : 
Editor : 
Creatives :